Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alligator Bioscience AB ( (SE:ATORX) ) has shared an update.
Alligator Bioscience has released its financial calendar for 2026, detailing key dates for shareholders and stakeholders, including the submission deadline for resolutions, various interim and annual reports, and the Annual General Meeting. This announcement provides stakeholders with a clear timeline for the company’s financial disclosures and meetings, which is crucial for maintaining transparency and engagement with investors.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company based in Lund, Sweden, specializing in the development of clinical-stage tumor-directed antibody drugs targeting the CD40 receptor. This approach is designed to enhance T cell priming and counteract the immunosuppressive nature of the tumor microenvironment, offering potential benefits for cancer patients. The company’s lead drug candidate, mitazalimab, is progressing towards Phase 3 development, having shown promising survival data in metastatic pancreatic cancer patients during Phase 2 trials. Alligator Bioscience is listed on Nasdaq Stockholm under the ticker ATORX.
Average Trading Volume: 4,523,492
Technical Sentiment Signal: Sell
Current Market Cap: SEK345.3M
For detailed information about ATORX stock, go to TipRanks’ Stock Analysis page.